Neoadjuvant combination therapy with anti-PD-1 and anti-CTLA4 agents has significantly improved long-term survival in patients with metastatic melanoma, yet not all patients respond to treatment. Resp…

Read more about 'Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures'...

Posted in Research; Posted 3 months ago Less than a minute to read